Pharmaceutical compounding rules, summarised from primary sources posts 91–120
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Genuine question rather than a rhetorical one: has anyone here actually observed pharmaceutical compounding rules, as opposed to read about it? The thread is long and I cannot tell.
Collapsed as off-topic by two members at trust level 3 or above
Understood, and I withdraw the assumption I opened with.
Coming back to post #90, because the follow-up matters more than the original answer.
What I would want before treating pharmaceutical compounding rules as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually missing.
If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.
I checked the source rather than the summary, and they differ.
Post-authorisation safety commitments are public and are one of the more useful sources for what a regulator considered uncertain at approval.
I had written a reply contradicting post #94 and deleted it. Here is what survived.
The failure mode on pharmaceutical compounding rules is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.
Taking post #96 at face value and following it one step further.
An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.
I have seen it go both ways, which is why I hedge.
That matches what I have seen, for whatever a single anecdote is worth.
Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold.
The variance between people here is larger than the effect being discussed.
Post #102 is right about the mechanism and I think understates the practical bit.
Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.
That matches what I was told, which is not the same as knowing it.
Coming back to post #101, because the follow-up matters more than the original answer.
On pharmaceutical compounding rules, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.
If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.
Adding the measurement that post #102 says would settle it.
Two claims get bundled together under pharmaceutical compounding rules and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one — this is why — usually is not.
Almost every disagreement in threads like this one dissolves once you say which of the two you are making.
Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.
I had written a reply contradicting post #104 and deleted it. Here is what survived.
Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold.
Adding the caveat now so it does not have to be extracted later.
Taking post #106 at face value and following it one step further.
What would change my mind on pharmaceutical compounding rules is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than pretend to more.
Post #108 and I disagree about the size of the effect, not about the direction.
Speaking only to pharmaceutical compounding rules as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the variance between people is larger than the effect.
Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.
I looked this up rather than remembered it, which is the right order.
The version of pharmaceutical compounding rules that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.
Take the reasoning and check the arithmetic; I do not always get it right.
Adding a small correction to the pharmaceutical compounding rules summary above rather than a disagreement with it. The substance holds; one of the figures is out by a factor that matters.
Where I part company with post #115, and it is a narrow parting.
Posting my pharmaceutical compounding rules numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted a particular answer.
Post #115 is the version of this I will quote in future. One addition.
Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable.
The honest answer is that it depends, and here is what it depends on.
Post #115 and I disagree about the size of the effect, not about the direction.
What I would check first on pharmaceutical compounding rules is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.
Taking post #119 at face value and following it one step further.
Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.
Anyone who has looked at this more carefully, please correct the record.